Global Congenital Hyperinsulinism Treatment Market: Key Developments
Glucagon, one of the primary medication of congenital hyperinsulinism shows promising results in treating congenital hyperinsulinism. For instance, in March 16, 2022, Xeris Pharmaceuticals, Inc., a biopharmaceutical company, develop a therapy for patients populations in endocrinology, a GVOKE kit (Glucagon Injection), containing liquid stable glucagon which is used to treat congenital hyperinsulinism. GVOKE was evaluated in a clinical trial in 31 pediatric patients with type 1 diabetes 100% (30/30) of pediatric patients had their glucose levels raise to safe levels.
This kit is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
Congenital Hyperinsulinism Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients